Shares of Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) have been assigned a consensus rating of “Buy” from the seven brokerages that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $39.50.

Several brokerages have recently issued reports on BHVN. Zacks Investment Research upgraded shares of Biohaven Pharmaceutical Holding Co from a “sell” rating to a “hold” rating in a report on Friday, September 8th. BidaskClub upgraded shares of Biohaven Pharmaceutical Holding Co from a “buy” rating to a “strong-buy” rating in a report on Thursday, September 7th. Needham & Company LLC reiterated a “buy” rating and set a $43.00 price target (up previously from $30.00) on shares of Biohaven Pharmaceutical Holding Co in a research note on Wednesday, September 13th. Piper Jaffray Companies reiterated a “buy” rating and set a $54.00 price target on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, September 12th. Finally, Morgan Stanley increased their price target on shares of Biohaven Pharmaceutical Holding Co from $28.00 to $47.00 and gave the stock an “overweight” rating in a research note on Monday, September 25th.

Shares of Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN) traded up $0.21 during trading on Monday, hitting $29.65. 313,933 shares of the stock traded hands, compared to its average volume of 239,921. Biohaven Pharmaceutical Holding Co has a fifty-two week low of $17.00 and a fifty-two week high of $39.51.

ILLEGAL ACTIVITY WARNING: “Biohaven Pharmaceutical Holding Co Ltd (BHVN) Receives Average Recommendation of “Buy” from Brokerages” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.watchlistnews.com/biohaven-pharmaceutical-holding-co-ltd-bhvn-receives-average-recommendation-of-buy-from-brokerages/1684033.html.

In other news, VP Kimberly Gentile sold 5,000 shares of the firm’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $29.28, for a total value of $146,400.00. Following the completion of the sale, the vice president now owns 5,000 shares in the company, valued at approximately $146,400. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider John Tilton sold 30,000 shares of the firm’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $29.25, for a total transaction of $877,500.00. Following the completion of the sale, the insider now owns 30,000 shares of the company’s stock, valued at approximately $877,500. The disclosure for this sale can be found here. In the last quarter, insiders have sold 185,000 shares of company stock valued at $5,435,400.

Several hedge funds have recently added to or reduced their stakes in the company. Nationwide Fund Advisors acquired a new stake in shares of Biohaven Pharmaceutical Holding Co in the 3rd quarter worth $214,000. State of Wisconsin Investment Board acquired a new stake in shares of Biohaven Pharmaceutical Holding Co in the 3rd quarter worth $262,000. Deschutes Portfolio Strategy LLC acquired a new stake in shares of Biohaven Pharmaceutical Holding Co in the 3rd quarter worth $374,000. Rhumbline Advisers acquired a new stake in shares of Biohaven Pharmaceutical Holding Co in the 3rd quarter worth $395,000. Finally, Sigma Planning Corp acquired a new stake in shares of Biohaven Pharmaceutical Holding Co in the 3rd quarter worth $561,000.

Biohaven Pharmaceutical Holding Co Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Analyst Recommendations for Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.